East Asian patients have reduced anti-ischemic benefits and increased bleeding risk
during antithrombotic therapies compared with Caucasian patients. As potent P2Y (12)
receptor inhibitors (e.g., ticagrelor and prasugrel) and direct oral anticoagulants
are commonly used in current daily practice, the unique risk-benefit trade-off in
East Asians has been a topic of emerging interest. In this article, we propose updated
evidence and future directions of antithrombotic treatment in East Asian patients.
